Table I.
Characteristics of the study population.
| Parameter | Value |
|---|---|
| Age (years), mean ± SD | 77.38±8.29 |
| CCI, median (range) | 4 (2-12) |
| Sex, n (%) | |
| Female | 69 (48.3) |
| Male | 74 (51.7) |
| Comorbidities, n (%) | |
| None | 15 (10.5) |
| Respiratory disease (COPD, asthma, ILD, OSA) | 9 (6.3) |
| Obesity | 3 (2.1) |
| Diabetes mellitus | 31(22) |
| Arterial hypertension | 65 (45.5) |
| Cardiovascular disease (ischemic stroke, arrhythmia, coronary artery disease, myocardial infarction) | 57 (39.9) |
| Heart failure | 12 (8.4) |
| Autoimmune disease | 11 (7.7) |
| Haematological malignancy | 13 (9.1) |
| Solid malignant neoplasm | 4 (2.8) |
| Renal disease | 30 (21.1) |
| Solid organ transplantation | 18 (12.6) |
| Vaccination status, n (%) | |
| Unvaccinated | 25 (17.5) |
| Vaccinated with two doses | 53 (37.1) |
| Vaccinated with at least three doses | 65 (45.4) |
| Progression to severe disease | 6 (4.2) |
| Mortality within 28 days | 5 (3.5) |
CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease; OSA, obstructive sleep apnoea; SD, standard deviation.